- Home
- INKT vs CUE Comparison
INKT vs CUE Comparison
Compare INKT & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INKT
- CUE
- Stock Information
- Founded
- INKT 2017
- CUE 2014
- Country
- INKT United States
- CUE United States
- Employees
- INKT N/A
- CUE N/A
- Industry
- INKT Medicinal Chemicals and Botanical Products
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- INKT Health Care
- CUE Health Care
- Exchange
- INKT Nasdaq
- CUE Nasdaq
- Market Cap
- INKT 69.2M
- CUE 61.1M
- IPO Year
- INKT 2021
- CUE 2018
- Fundamental
- Price
- INKT $11.14
- CUE $0.58
- Analyst Decision
- INKT Buy
- CUE Strong Buy
- Analyst Count
- INKT 2
- CUE 2
- Target Price
- INKT $35.00
- CUE $3.00
- AVG Volume (30 Days)
- INKT 21.8K
- CUE 385.4K
- Earning Date
- INKT 11-14-2025
- CUE 11-12-2025
- Dividend Yield
- INKT N/A
- CUE N/A
- EPS Growth
- INKT N/A
- CUE N/A
- EPS
- INKT N/A
- CUE N/A
- Revenue
- INKT N/A
- CUE $7,100,000.00
- Revenue This Year
- INKT N/A
- CUE N/A
- Revenue Next Year
- INKT N/A
- CUE N/A
- P/E Ratio
- INKT N/A
- CUE N/A
- Revenue Growth
- INKT N/A
- CUE N/A
- 52 Week Low
- INKT $4.56
- CUE $0.54
- 52 Week High
- INKT $76.00
- CUE $1.75
- Technical
- Relative Strength Index (RSI)
- INKT 28.19
- CUE 33.13
- Support Level
- INKT $13.13
- CUE $0.57
- Resistance Level
- INKT $14.20
- CUE $0.82
- Average True Range (ATR)
- INKT 0.78
- CUE 0.08
- MACD
- INKT -0.21
- CUE -0.01
- Stochastic Oscillator
- INKT 9.43
- CUE 8.11
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.